Mereo BioPharma Faces Class Action Over Failed Setrusumab Trials

Reuters

Feb 14

Mereo BioPharma Faces Class Action Over Failed Setrusumab Trials

A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased the company’s American Depositary Shares between June 5, 2023, and December 26, 2025. The complaint alleges that Mereo and certain executives made materially false and misleading statements regarding the likelihood of success of its Phase 3 clinical trials for setrusumab, a treatment for Osteogenesis Imperfecta. According to the lawsuit, the company repeatedly expressed confidence that its ORBIT and COSMIC trials would achieve statistical significance in reducing annualized fracture rates and position setrusumab for regulatory success, while concealing adverse facts about the studies’ progress. On December 29, 2025, Mereo disclosed that neither trial achieved its primary endpoint, leading to a sharp decline in its share price by over 87 percent. Investors have until April 6, 2026, to seek appointment as lead plaintiff.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602131113PRIMZONEFULLFEED9654592) on February 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611169974"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611169974\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611169974?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-14 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611169974","market":"nz","top_or_hot":-1,"title":"Mereo BioPharma Faces Class Action Over Failed Setrusumab Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mereo BioPharma Faces Class Action Over Failed Setrusumab Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased the company’s American Depositary Shares between June 5, 2023, and December 26, 2025. The complaint alleges that Mereo and certain executives made materially false and misleading statements regarding the likelihood of success of its Phase 3 clinical trials for setrusumab, a treatment for Osteogenesis Imperfecta. According to the lawsuit, the company repeatedly expressed confidence that its ORBIT and COSMIC trials would achieve statistical significance in reducing annualized fracture rates and position setrusumab for regulatory success, while concealing adverse facts about the studies’ progress. On December 29, 2025, Mereo disclosed that neither trial achieved its primary endpoint, leading to a sharp decline in its share price by over 87 percent. Investors have until April 6, 2026, to seek appointment as lead plaintiff.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602131113PRIMZONEFULLFEED9654592) on February 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mereo BioPharma Faces Class Action Over Failed Setrusumab Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMereo BioPharma Faces Class Action Over Failed Setrusumab Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-14 00:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mereo BioPharma Faces Class Action Over Failed Setrusumab Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased the company’s American Depositary Shares between June 5, 2023, and December 26, 2025. The complaint alleges that Mereo and certain executives made materially false and misleading statements regarding the likelihood of success of its Phase 3 clinical trials for setrusumab, a treatment for Osteogenesis Imperfecta. According to the lawsuit, the company repeatedly expressed confidence that its ORBIT and COSMIC trials would achieve statistical significance in reducing annualized fracture rates and position setrusumab for regulatory success, while concealing adverse facts about the studies’ progress. On December 29, 2025, Mereo disclosed that neither trial achieved its primary endpoint, leading to a sharp decline in its share price by over 87 percent. Investors have until April 6, 2026, to seek appointment as lead plaintiff.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602131113PRIMZONEFULLFEED9654592) on February 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014039.USD","symbol_name":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL2xzVHV:1","article_id":"2611169974","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611169974","pubTimestamp":1770999240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased the company’s American Depositary Shares between June 5, 2023, and December 26, 2025. The complaint alleges that Mereo and certain executives made materially false and misleading statements regarding the likelihood of success of its Phase 3 clinical trials for setrusumab, a treatment for Osteogenesis Imperfecta. According to the lawsuit, the company repeatedly expressed confidence that its ORBIT and COSMIC trials would achieve statistical significance in reducing annualized fracture rates and position setrusumab for regulatory success, while concealing adverse facts about the studies’ progress. On December 29, 2025, Mereo disclosed that neither trial achieved its primary endpoint, leading to a sharp decline in its share price by over 87 percent. Investors have until April 6, 2026, to seek appointment as lead plaintiff.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4588":"碎股","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","MREO":"Mereo Biopharma Group Plc","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4505":"高瓴资本持仓"},"translate_title":"Mereo BioPharma因Setrusumab试验失败而面临集体诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MREO":0.9,"NDAQ":0.9},"content_text":"Mereo BioPharma Faces Class Action Over Failed Setrusumab Trials\n    \n\n        A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased the company’s American Depositary Shares between June 5, 2023, and December 26, 2025. The complaint alleges that Mereo and certain executives made materially false and misleading statements regarding the likelihood of success of its Phase 3 clinical trials for setrusumab, a treatment for Osteogenesis Imperfecta. According to the lawsuit, the company repeatedly expressed confidence that its ORBIT and COSMIC trials would achieve statistical significance in reducing annualized fracture rates and position setrusumab for regulatory success, while concealing adverse facts about the studies’ progress. On December 29, 2025, Mereo disclosed that neither trial achieved its primary endpoint, leading to a sharp decline in its share price by over 87 percent. Investors have until April 6, 2026, to seek appointment as lead plaintiff.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602131113PRIMZONEFULLFEED9654592) on February 13, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}